Výsledky vyhledávání

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response

Autor: Thomas F. Gajewski, Evan J. Lipson, Tricia R. Cottrell, F.S. Hodi, Julie E. Stein, Megan Wind-Rotolo, Janis M. Taube, Shailender Bhatia, Abha Soni, Robin Edwards, Liudmila V Danilova, William H. Sharfman, W J Urba

Publikováno v: Annals of Oncology. 30:589-596

BACKGROUND: With increasing anti-PD-1 therapy use in patients with melanoma and other tumor types, there is interest in developing early on-treatment biomarkers that correlate with long-term patient outcome. An understanding of the pathologic feature

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6387bb3c32bd7bb71d9cb0b5fe9dfa20
https://doi.org/10.1093/annonc/mdz019

Zobrazit plný text záznamu

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma

Autor: Barry L. Gause, Edward L. Korn, Diane Stevens, M Sznol, Brendan D. Curti, Kevin C. Conlon, Langdon L. Miller, William H. Sharfman, Dan L. Longo, John E. Janik, W J Urba, John W. Smith

Publikováno v: Blood. 97:1942-1946

We conducted a phase II randomized trial of recombinant granculocyte-macrophage colony-stimulating factor (GM-CSF) administered before topotecan chemotherapy to determine whether it could prevent myelosuppression and to determine the antitumor activi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d401e0ddfdfd22d8b7920c7352584b
https://doi.org/10.1182/blood.v97.7.1942

Zobrazit plný text záznamu

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer

Autor: Kevin C. Conlon, Louis A. VanderMolen, Dan L. Longo, John E. Janik, William C. Kopp, Ronald G. Steis, John W. Smith, M Sznol, Robert G. Fenton, Jon Holmlund, William Sharfman, S P Creekmore, Barry L. Gause, W J Urba

Publikováno v: Journal of Clinical Oncology. 14:2234-2241

PURPOSE Although high-dose interleukin-2 (IL-2) can produce durable remissions in a subset of responding patients with renal cell carcinoma (RCC), this occurs in the setting of significant toxicity. The purpose of this study is to define the maximum-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2f047f45ba7103730d691c23933d6c1
https://doi.org/10.1200/jco.1996.14.8.2234

Zobrazit plný text záznamu

Phase II Trial of Interleukin 1 and Indomethacin in Treatment of Metastatic Melanoma

Autor: William C. Kopp, Ronald G. Steis, G. C. Powers, John E. Janik, Robert G. Fenton, Kevin C. Conlon, W G Alvord, Joost J. Oppenheim, M Sznol, Langdon L. Miller, S P Creekmore, Barry L. Gause, A. E. Beauchamp, W J Urba, W. H. Sharfman, Jon Holmlund, John W. Smith, Dan L. Longo, Brendan D. Curti

Publikováno v: JNCI Journal of the National Cancer Institute. 88:44-49

BACKGROUND The rising incidence of malignant melanoma and the lack of curative therapies for metastatic disease represent a therapeutic challenge. New agents effective in treating this disease are needed. PURPOSE Because of the additive antitumor eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39bcb6c04cc199f7935b8fc04cfbda10
https://doi.org/10.1093/jnci/88.1.44

Zobrazit plný text záznamu

Immunomodulatory Effects of Interferon-?? in Patients with Metastatic Malignant Melanoma

Autor: P M Guyre, Dan L. Longo, C H Ewel, J W Smith nd, William C. Kopp, C Main, W G Alvord, Ronald G. Steis, W J Urba

Publikováno v: Journal of Immunotherapy. 13:181-190

Interferon-gamma (IFN-gamma) is a potent monocyte/macrophage activating agent that in animal models exhibits a bell-shaped dose-response curve of immunomodulatory activity and antitumor efficacy. Previous clinical trials of IFN-gamma conducted at the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e3968a14e5c6d08f9324931e75829bf
https://doi.org/10.1097/00002371-199304000-00005

Zobrazit plný text záznamu

Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes

Autor: K C Conlon, A C Ochoa, W C Kopp, J R Ortaldo, W J Urba, D L Longo, H A Young

Publikováno v: The Journal of Immunology. 149:3278-3289

Treatment of T lymphocytes with antibodies directed against the T cell receptor CD3 complex results in cellular activation that can be augmented by costimulation through other cell surface receptors. The activities of anti-CD3-stimulated human CD4+ P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9ccdce8f647074dd31757a52ec45c987
https://doi.org/10.4049/jimmunol.149.10.3278

Zobrazit plný text záznamu

Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells

Autor: C M Loeffler, M J Smyth, D L Longo, W C Kopp, L K Harvey, H R Tribble, J E Tase, W J Urba, A S Leonard, H A Young

Publikováno v: The Journal of Immunology. 149:949-956

The causes of the decreased immune responsiveness in tumor-bearing hosts are incompletely understood. The impact of a decreased immune response in cancer patients on the clinical response in immunotherapy trials has not been evaluated. The present re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::676732db330c236fa99377d4bc1f58a7
https://doi.org/10.4049/jimmunol.149.3.949

Zobrazit plný text záznamu

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies

Autor: Kevin C. Conlon, W J Urba, J W Smith nd, Brendan D. Curti, John E. Janik, Robert G. Fenton, Ronald G. Steis, W. H. Sharfman, L J Elwood, Langdon L. Miller

Publikováno v: Journal of Clinical Oncology. 10:1141-1152

PURPOSE A phase I trial was undertaken because interleukin-1 alpha (IL-1 alpha) possesses antiproliferative, immunostimulatory, antiinfection, myeloprotective, and myelorestorative properties that could be beneficial in cancer treatment. PATIENTS AND

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::463aa858e965d2e7f83fe52780fbc12b
https://doi.org/10.1200/jco.1992.10.7.1141

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání